# Study of ALTO-300 in MDD

> **NCT05922878** · PHASE2 · RECRUITING · sponsor: **Alto Neuroscience** · enrollment: 321 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ALTO-300
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05922878
- **Lead sponsor:** Alto Neuroscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-08
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 321 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922878, "Study of ALTO-300 in MDD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05922878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*